Trial Profile
A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Iadademstat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms ALICE
- Sponsors Oryzon
- 13 Dec 2022 Final Results( data cut-off June 30, 2022; n=34) assessing safety and tolerability of Iadademstat Combination with Azacitidine in First Line Acute Myeloid Leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2022 Status changed from active, no longer recruiting to completed, according to an Oryzon media release.
- 12 Dec 2022 According to an Oryzon media release, final data from this study presented at the 64th American Society of Hematology (ASH) Annual Conference